Literature DB >> 10344410

Effects of serotonin re-uptake inhibition on ventilatory control in goats.

D R Henderson1, D M Konkle, G S Mitchell.   

Abstract

Fluoxetine (Prozac) inhibits serotonin (5-HT) re-uptake. thereby enhancing serotonergic effects. Since serotonin is known to affect ventilation in a variety of circumstances, we investigated the effects of chronic serotonin re-uptake inhibition with fluoxetine on selected ventilatory responses including: (1) eupnea; (2) the hypercapnic ventilatory response at rest; (3) the exercise ventilatory response and (4) repeated trials of hypercapnic exercise. Ventilatory and arterial blood gases were measured in goats (n = 5) at rest, during steady-state treadmill exercise, and during successive rest/exercise trials with increased respiratory dead space (0.4-0.6 L). Fluoxetine was administered (> or = 4 weeks, 1 mg/kg, SQ, SID) and protocols were repeated. Following fluoxetine, PaCO2 was increased in most conditions studied; however, no differences were seen in exercise PaCO2 regulation or ventilatory responses pre- versus post-fluoxetine. We conclude that chronic fluoxetine slightly depresses respiratory control at rest, but, has minimal effects during exercise or with mild hypercapnia during rest or exercise in goats.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10344410     DOI: 10.1016/s0034-5687(98)00103-0

Source DB:  PubMed          Journal:  Respir Physiol        ISSN: 0034-5687


  4 in total

1.  Spinal serotonin receptor activation modulates the exercise ventilatory response with increased dead space in goats.

Authors:  G S Mitchell; D L Turner; D R Henderson; K T Foley
Journal:  Respir Physiol Neurobiol       Date:  2008-02-29       Impact factor: 1.931

2.  Chronic serotonin-norepinephrine reuptake transporter inhibition modifies basal respiratory output in adult mouse in vitro and in vivo.

Authors:  Kelly A Warren; Irene C Solomon
Journal:  Respir Physiol Neurobiol       Date:  2012-07-31       Impact factor: 1.931

3.  Study protocol: a phase III randomised, double-blind, parallel arm, stratified, block randomised, placebo-controlled trial investigating the clinical effect and cost-effectiveness of sertraline for the palliative relief of breathlessness in people with chronic breathlessness.

Authors:  Gareth J Watts; Katherine Clark; Meera Agar; Patricia M Davidson; Christine McDonald; Lawrence T Lam; Dimitar Sajkov; Nicola McCaffrey; Matthew Doogue; Amy P Abernethy; David C Currow
Journal:  BMJ Open       Date:  2016-11-29       Impact factor: 2.692

4.  Effects of sedative psychotropic drugs combined with oxycodone on respiratory depression in the rat.

Authors:  Lin Xu; Ashok Krishna; Sharron Stewart; Katherine Shea; Rebecca Racz; James L Weaver; Donna A Volpe; Nageswara R Pilli; Suresh Narayanasamy; Jeffry Florian; Vikram Patel; Murali K Matta; Marc B Stone; Hao Zhu; Michael C Davis; David G Strauss; Rodney Rouse
Journal:  Clin Transl Sci       Date:  2021-06-16       Impact factor: 4.689

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.